DelveInsight's "Psoriatic Arthritis Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Psoriatic Arthritis market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Psoriatic Arthritis drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Psoriatic Arthritis treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Psoriatic Arthritis: An Overview
Psoriatic arthritis (PsA) is a heterogeneous chronic inflammatory rheumatic disease characterized by pain, stiffness, swollen joints, joint erosion, and bone formation. Clinical manifestations vary significantly between patients. It can present with oligoarticular joint involvement, typically asymmetric, or as a polyarticular disease affecting five or more joints, usually with an asymmetric distribution similar to rheumatoid arthritis
PsA etiology remains still unknown, but pathogenetic models suggest a complex interaction between multiple genetic (i.e., HLA-B*27 and HLA-C*0602 alleles), environmental (i.e., infections, biomechanical stress or trauma), and immunologic factors (i.e., T helper lymphocyte subsets)
Several factors can increase your risk of psoriatic arthritis, including Psoriasis: Having psoriasis is the single greatest risk factor for developing psoriatic arthritis, family history: Many people with psoriatic arthritis have a parent or a sibling with the disease also anyone can develop psoriatic arthritis, it occurs most often in adults between the ages of 30 and 55.
Psoriatic Arthritis Market Key Facts
-
The total prevalent patient population of psoriatic arthritis (PsA) in the 7MM countries was close to 1.5 million in 2021.
-
According to DelveInsight’s analysts, in 2022, the total diagnosed cases of PsA in the US were approximately 560,000 cases and more than 690,000 cases in EU4 and the UK which are expected to rise in the upcoming years.
-
Several Psoriatic Arthritis companies are working robustly on many new therapies, such as bimekizumab (UCB Biopharma), tildrakizumab (Sun Pharmaceutical), deucravacitinib (BMS), and izokibep (Affibody AB).
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Psoriatic Arthritis pipeline therapies. It also thoroughly assesses the Psoriatic Arthritis market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Psoriatic Arthritis drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Psoriatic Arthritis Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Psoriatic Arthritis epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Psoriatic Arthritis epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Psoriatic Arthritis Epidemiology, Segmented as -
-
Total Prevalent Cases of Psoriatic Arthritis [2019–2032]
-
Total Diagnosed Cases of Psoriatic Arthritis [2019–2032]
-
Gender-specific Cases of Psoriatic Arthritis [2019–2032]
-
Age-specific Cases of Psoriatic Arthritis [2019–2032]
-
Severity-specific Cases of Psoriatic Arthritis [2019–2032]
Psoriatic Arthritis Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Psoriatic Arthritis market or expected to be launched during the study period. The analysis covers the Psoriatic Arthritis market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Psoriatic Arthritis drugs based on their sale and market share.
The report also covers the Psoriatic Arthritis pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Psoriatic Arthritis companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Psoriatic Arthritis Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/psoriatic-arthritis-market
Psoriatic Arthritis Therapeutics Analysis
PsA treatments aren’t one-size-fits-all; the current treatment strategy in PsA emphasizes a target-to-target approach to the prevalent domains. Advances in the knowledge of pathogenesis have led to the development of novel biologics beyond anti-TNFs. However, there is still a substantial proportion of patients who may not respond to certain treatment options. The current practice relies on the individualizing choice of treatment by matching the most severely affected domains of the patients with the best available evidence of the efficacies of drugs for those domains. When patients do not respond to treatment, shifting and cycling through different options would be the rational steps.
Several major pharma and biotech companies are developing therapies for Psoriatic Arthritis. Currently, Abbvie is leading the therapeutics market with its Psoriatic Arthritis drug candidates in the most advanced stage of clinical development.
Psoriatic Arthritis Companies Actively Working in the Therapeutics Market Include
Mylan, Celltrion, Fresenius Kabi, Pfizer, Fujifilm Kyowa Kirin Biologics, Amgen, Zydus cadilla, Sandoz, Shanghai Henlius Biotech, Hetero Biopharma, CinnaGen, Fresenius Kabi, Torrent Pharmaceuticals, Cipla, Biogen, AbbVie, Biocad, Boehringer Ingelheim, Sun Pharma Global, Gilead Sciences, UCB Biopharma, Formycon, Bristol-Myers Squibb, AbGenomics, Boehringer Ingelheim, Affibody, AltruBio, Bio-Thera Solutions, Dong-A ST, Synact Pharma, NeuClone, 3SBio, Qyuns Therapeutics, Kangpu Biopharmaceuticals, Alpine Immune Sciences, Akeso Biopharma, Polpharma Biologics, Avotres, Bio-Thera Solutions, Xbrane Biopharma, XBiotech, Innovimmune Biotherapeutics, Aclaris Therapeutics, Luye Pharma Group, Evelo, Levolta Pharmaceuticals, DNX Biopharmaceuticals, Mycenax Biotech, and many others.
Emerging and Marketed Psoriatic Arthritis Therapies Covered in the Report Include:
-
ABT-494: AbbVie
-
Risankizumab: Abbvie
And Many More
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
https://www.delveinsight.com/sample-request/psoriatic-arthritis-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Psoriatic Arthritis Competitive Intelligence Analysis
4. Psoriatic Arthritis Market Overview at a Glance
5. Psoriatic Arthritis Disease Background and Overview
6. Psoriatic Arthritis Patient Journey
7. Psoriatic Arthritis Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Psoriatic Arthritis Treatment Algorithm, Current Treatment, and Medical Practices
9. Psoriatic Arthritis Unmet Needs
10. Key Endpoints of Psoriatic Arthritis Treatment
11. Psoriatic Arthritis Marketed Therapies
12. Psoriatic Arthritis Emerging Drugs and Latest Therapeutic Advances
13. Psoriatic Arthritis Seven Major Market Analysis
14. Attribute Analysis
15. Psoriatic Arthritis Market Outlook (In US, EU5, and Japan)
16. Psoriatic Arthritis Companies Active in the Market
17. Psoriatic Arthritis Access and Reimbursement Overview
18. KOL Views on the Psoriatic Arthritis Market
19. Psoriatic Arthritis Market Drivers
20. Psoriatic Arthritis Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/psoriatic-arthritis-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
Cutaneous Lupus Erythematosus Market
"Cutaneous Lupus Erythematosus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Cutaneous Lupus Erythematosus market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Cutaneous Lupus Erythematosus market.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email:Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/market-research
